TMEM185A is a transmembrane protein with limited functional characterization in the provided literature. Its primary known association involves cancer biology, where it has been identified as a potential neantigen target in breast cancer with lymph node metastasis 1. In stage III serous ovarian carcinoma, TMEM185A expression is significantly down-regulated compared to normal tissue, clustering with other genes associated with poor prognosis markers 2. At the genomic level, TMEM185A is subject to copy number variation; it is duplicated in a complex chrX rearrangement on Xq28 associated with hemophilia A, though this duplication does not produce clinically detectable phenotypic effects beyond the primary F8 mutation, suggesting dosage-independent function 3. The protein contains transmembrane domains consistent with membrane localization. While GO annotations suggest roles in protein binding and dendrite-related functions, these aspects lack direct experimental support in the provided abstracts. The down-regulation in ovarian cancer and identification as a cancer-associated neoantigen suggest potential involvement in tumor biology, though the specific molecular mechanisms and physiological functions of TMEM185A remain unclear.